The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders.
Chiesi Farmaceutici SpA has disclosed imidazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Suzhou Puhe Biopharma Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Ningbo Newbay Medical Technology Co. Ltd. has identified poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has disclosed fused quinazoline compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of solid tumors.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described pyrazole-substituted cyclopentanol ester derivatives acting as CDK2/cyclin E1 and CDK2/cyclin A2 inhibitors reported to be useful for the treatment of cancer.
Viscient Biosciences LLC has divulged tryptanthrin derivatives acting as indoleamine 2,3-dioxygenase 2 (IDO-2) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Serpin Pharma LLC has identified serpin peptide derivatives acting as pro-low-density lipoprotein receptor-related protein 1 (LRP-1) agonists reported to be useful for the treatment of acute lung injury, eosinophilic esophagitis, viral infection, and acute and neuropathic pain, among others.
RSS